» Articles » PMID: 24962208

Drug Effects on the CVS in Conscious Rats: Separating Cardiac Output into Heart Rate and Stroke Volume Using PKPD Modelling

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 2014 Jun 26
PMID 24962208
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Previously, a systems pharmacology model was developed characterizing drug effects on the interrelationship between mean arterial pressure (MAP), cardiac output (CO) and total peripheral resistance (TPR). The present investigation aims to (i) extend the previously developed model by parsing CO into heart rate (HR) and stroke volume (SV) and (ii) evaluate if the mechanism of action (MoA) of new compounds can be elucidated using only HR and MAP measurements.

Experimental Approach: Cardiovascular effects of eight drugs with diverse MoAs (amiloride, amlodipine, atropine, enalapril, fasudil, hydrochlorothiazide, prazosin and propranolol) were characterized in spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto (WKY) rats following single administrations of a range of doses. Rats were instrumented with ascending aortic flow probes and aortic catheters/radiotransmitters for continuous recording of MAP, HR and CO throughout the experiments. Data were analysed in conjunction with independent information on the time course of the drug concentration following a mechanism-based pharmacokinetic-pharmacodynamic modelling approach.

Key Results: The extended model, which quantified changes in TPR, HR and SV with negative feedback through MAP, adequately described the cardiovascular effects of the drugs while accounting for circadian variations and handling effects.

Conclusions And Implications: A systems pharmacology model characterizing the interrelationship between MAP, CO, HR, SV and TPR was obtained in hypertensive and normotensive rats. This extended model can quantify dynamic changes in the CVS and elucidate the MoA for novel compounds, with one site of action, using only HR and MAP measurements. Whether the model can be applied for compounds with a more complex MoA remains to be established.

Citing Articles

Pharmacodynamic Model of the Hemodynamic Effects of Propofol and Remifentanil and Their Interaction with Noxious Stimulation.

Garraza-Obaldia M, Jaramillo S, Parra-Guillen Z, Valencia J, Gambus P, Troconiz I Pharmaceutics. 2025; 16(12.

PMID: 39771593 PMC: 11677492. DOI: 10.3390/pharmaceutics16121615.


Modelling hemodynamics regulation in rats and dogs to facilitate drugs safety risk assessment.

Morris C, Rolf M, Starnes L, Villar I, Pointon A, Kimko H Front Pharmacol. 2024; 15:1402462.

PMID: 39534082 PMC: 11555398. DOI: 10.3389/fphar.2024.1402462.


A tutorial for model-based evaluation and translation of cardiovascular safety in preclinical trials.

Kulesh V, Vasyutin I, Volkova A, Peskov K, Kimko H, Sokolov V CPT Pharmacometrics Syst Pharmacol. 2023; 13(1):5-22.

PMID: 37950388 PMC: 10787214. DOI: 10.1002/psp4.13082.


Evaluation of a Cardiovascular Systems Model for Design and Analysis of Hemodynamic Safety Studies.

Fu Y, Snelder N, Guo T, van der Graaf P, van Hasselt J Pharmaceutics. 2023; 15(4).

PMID: 37111660 PMC: 10143046. DOI: 10.3390/pharmaceutics15041175.


A novel cardiovascular systems model to quantify drugs effects on the inter-relationship between contractility and other hemodynamic variables.

Fu Y, Taghvafard H, Said M, Rossman E, Collins T, Billiald-Desquand S CPT Pharmacometrics Syst Pharmacol. 2022; 11(5):640-652.

PMID: 35213797 PMC: 9124360. DOI: 10.1002/psp4.12774.


References
1.
Perez-Reyes E, Van Deusen A, Vitko I . Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2008; 328(2):621-7. PMC: 2682278. DOI: 10.1124/jpet.108.145672. View

2.
Gasparyan A, Ayvazyan L, Cocco G, Kitas G . Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des. 2012; 18(11):1543-55. DOI: 10.2174/138161212799504759. View

3.
Danhof M, de Lange E, Della Pasqua O, Ploeger B, Voskuyl R . Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci. 2008; 29(4):186-91. DOI: 10.1016/j.tips.2008.01.007. View

4.
Pinto Y, Paul M, Ganten D . Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res. 1998; 39(1):77-88. DOI: 10.1016/s0008-6363(98)00077-7. View

5.
Belpaire F, De Smet F, Vynckier L, Vermeulen A, Rosseel M, Bogaert M . Effect of aging on the pharmcokinetics of atenolol, metoprolol and propranolol in the rat. J Pharmacol Exp Ther. 1990; 254(1):116-22. View